Pericardial Manifestations in Inflammatory Bowel Disease: A Report of Two Cases

Qazi, Taha; Christian, Kaci E.; Farraye, Francis A.; Cross, Raymond

doi:10.1093/crocol/otz028

Cited by 5 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our case, the extensive infectious, rheumatologic, and malignancy workup combined with the exudative pericardial fluid analysis, and presence of a noninfectious fibrinous effusion were all most consistent with previous reports of IBD‐related pericarditis. Our patient had been on adalimumab long‐term, and most reported cases of anti‐TNF therapy‐related pericarditis occurred temporally with initiation of therapy 7 . Thus, it was felt that the pericarditis most likely reflected extraintestinal Crohn's disease.…”

Section: Discussionmentioning

confidence: 92%

Crohn's pericarditis identified with point‐of‐care ultrasonography: A case report

Levy

Handel

Tierney

2020

J of Clinical Ultrasound

View full text Add to dashboard Cite

We report the case of a 71-year-old male with Crohn's disease, shortness of breath, and chest pain that highlights cardiac involvement in inflammatory bowel disease and the role of point-of-care ultrasonography using an alternate cardiac ultrasound window in making the diagnosis of Crohn's pericarditis. The role of ultrasonography in diagnosis and management of inflammatory bowel disease focuses primarily on intestinal pathology. Cardiac involvement is a rare but clinically impactful extraintestinal manifestation, the diagnosis of which benefits from ultrasonography if the clinician performing and interpreting the exam is aware of the possibility and understands the potential value of whole-body ultrasonography as part of a physical exam.

show abstract

Section: Discussionmentioning

confidence: 92%

Crohn's pericarditis identified with point‐of‐care ultrasonography: A case report

Levy

Handel

Tierney

2020

J of Clinical Ultrasound

View full text Add to dashboard Cite

show abstract

“…Infliximab-induced pericarditis and pleural effusions are rarely reported in the literature [1]. Drug-induced lupus with infliximab therapy in CD patients has only been seen in 0.6% to 1.6% of cases [10,11].…”

Section: Discussionmentioning

confidence: 99%

“…Crohn's disease (CD) is a chronic inflammatory disease associated with intestinal and extraintestinal manifestations [1]. It is characterized by chronic, relapsing transmural inflammation that can present as skip lesions throughout the gastrointestinal tract and manifests as chronic abdominal pain, diarrhea, obstruction, and/or perianal lesions.…”

Section: Introductionmentioning

confidence: 99%

Antitumor Necrosis Factor-Alpha (TNF-α) Infliximab-Induced Pleural Effusion and Pericarditis in Crohn’s Disease

Fonseca

Sunny

Felipez

2021

Case Reports in Pediatrics

View full text Add to dashboard Cite

Crohn’s disease (CD) is a chronic inflammatory disease that can be associated with intestinal and extraintestinal manifestations. Some patients are treated with infliximab, an antitumor necrosis factor-alpha (TNF-α) agent, to help them achieve and maintain clinical and biochemical remission. However, some patients with CD can present severe adverse effects such as drug-induced lupus and rarely present with pleural space and pericardium involvement. We report a case of an 18-year-old Hispanic male with CD who acquired anti-TNF-α-induced lupus after infliximab therapy presenting with pleural effusion and pericarditis. The patient presented with a 2-week history of pleuritic chest pain. Initial laboratory workup was remarkable for leukocytosis and increased inflammatory markers. Imaging and cardiovascular studies were consistent with pericarditis and pleural effusions. Serositis was initially thought to be reactive secondary to the current Mycoplasma pneumoniae infection. He was treated with colchicine 0.6 mg PO TID for six weeks and azithromycin 500 mg PO for seven days. Pain improved after discharge but resurfaced on the day of infliximab infusion. Imaging and cardiovascular studies demonstrated the persistence of pleural effusions and pericarditis. Ultrasound-guided thoracentesis was consistent with exudative pleural effusions. Rheumatological workup was remarkable for increased antihistone antibodies, consistent with drug-induced lupus. Infliximab-induced pericarditis and pleural effusions are rarely reported in the literature. It is thought that infliximab may have a proinflammatory activity or have a delayed type III hypersensitivity reaction. The first line of therapy of anti-TNF-α-induced lupus is the withdrawal of the offending drug. Our patient is unique as few cases of anti-TNF-α-induced pleural effusion and pericarditis in CD are reported. After discontinuing the offending drug, ustekinumab was started, and maintaining a steroid and colchicine regimen, the patient’s chest pain improved. Antihistone antibodies have returned to normal one month after starting ustekinumab.

show abstract

Multiple drugs

2020

Reactions Weekly

View full text Add to dashboard Cite

Pericardial Manifestations in Inflammatory Bowel Disease: A Report of Two Cases

Cited by 5 publications

References 15 publications

Crohn's pericarditis identified with point‐of‐care ultrasonography: A case report

Crohn's pericarditis identified with point‐of‐care ultrasonography: A case report

Antitumor Necrosis Factor-Alpha (TNF-α) Infliximab-Induced Pleural Effusion and Pericarditis in Crohn’s Disease

Multiple drugs

Contact Info

Product

Resources

About